Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 10:15AM ET
2.34
Dollar change
+0.07
Percentage change
2.86
%
Index- P/E17.16 EPS (ttm)0.14 Insider Own14.28% Shs Outstand40.34M Perf Week-3.51%
Market Cap94.61M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float34.73M Perf Month-16.61%
Income5.52M PEG- EPS next Q- Inst Own13.31% Short Float1.68% Perf Quarter5.90%
Sales1.34M P/S70.61 EPS this Y2.38% Inst Trans-39.92% Short Ratio3.37 Perf Half Y11.19%
Book/sh4.06 P/B0.57 EPS next Y- ROA2.89% Short Interest0.58M Perf Year2.41%
Cash/sh4.00 P/C0.58 EPS next 5Y- ROE3.50% 52W Range1.67 - 5.25 Perf YTD1.08%
Dividend Est.- P/FCF- EPS past 5Y- ROI3.37% 52W High-55.52% Beta1.87
Dividend TTM- Quick Ratio3.06 Sales past 5Y-50.43% Gross Margin85.37% 52W Low39.82% ATR (14)0.16
Dividend Ex-Date- Current Ratio3.06 EPS Y/Y TTM114.55% Oper. Margin-1176.79% RSI (14)37.19 Volatility6.91% 6.30%
Employees15 Debt/Eq0.32 Sales Y/Y TTM-50.43% Profit Margin412.31% Recom3.00 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q252.63% Payout0.00% Rel Volume0.61 Prev Close2.27
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% Earnings- Avg Volume173.51K Price2.34
SMA20-11.17% SMA50-19.42% SMA200-12.70% Trades Volume16,905 Change2.86%
Date Action Analyst Rating Change Price Target Change
Jan-12-23Downgrade Canaccord Genuity Buy → Hold $30 → $3
Feb-18-22Initiated Cantor Fitzgerald Overweight $20
Apr-20-21Initiated Canaccord Genuity Buy $27
Feb-09-21Initiated National Securities Buy
Dec-03-20Initiated Alliance Global Partners Buy $11
Mar-11-20Initiated Aegis Capital Buy $5.50
Sep-11-19Initiated Ladenburg Thalmann Buy $7
Dec-11-17Resumed B. Riley FBR, Inc. Buy $20
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Mar-19-24 09:00AM
Mar-07-24 10:53AM
Feb-20-24 08:30AM
Nov-10-23 05:03AM
Oct-24-23 08:30AM
10:13AM Loading…
Oct-05-23 10:13AM
Sep-22-23 11:38AM
Sep-21-23 06:11PM
04:05PM
Sep-13-23 09:00AM
Aug-02-23 07:45AM
Jun-20-23 07:55AM
Jun-17-23 09:54AM
May-30-23 11:06AM
May-18-23 07:55AM
09:05AM Loading…
May-15-23 09:05AM
May-12-23 01:03PM
May-02-23 10:51AM
May-01-23 04:45PM
Mar-27-23 06:57AM
Feb-09-23 07:55AM
Jan-25-23 08:05AM
Jan-12-23 12:30PM
11:50AM
08:02AM
06:19AM
Jan-11-23 08:00PM
Jan-08-23 07:38AM
Jan-04-23 07:55AM
Dec-21-22 08:25AM
08:30AM Loading…
Dec-05-22 08:30AM
Nov-29-22 08:40AM
Nov-21-22 10:45AM
Nov-17-22 01:12PM
12:25PM
Nov-16-22 05:06AM
Nov-14-22 07:55AM
Nov-10-22 04:30PM
Nov-09-22 08:40AM
Oct-17-22 08:07AM
Oct-07-22 11:06AM
08:40AM
Sep-13-22 11:59AM
08:40AM
Sep-06-22 07:55AM
Aug-25-22 09:15AM
Aug-01-22 07:40AM
Jul-26-22 07:55AM
Jul-12-22 02:22PM
Jul-11-22 07:55AM
Jul-08-22 05:56PM
Jul-07-22 07:55AM
Jun-01-22 07:55AM
May-24-22 08:10AM
May-18-22 07:55AM
May-10-22 07:12AM
May-03-22 08:10AM
Apr-27-22 08:10AM
Apr-05-22 08:25AM
Apr-04-22 08:25AM
Mar-29-22 08:25AM
Mar-22-22 08:25AM
Mar-16-22 08:25AM
Mar-10-22 08:25AM
Feb-23-22 11:25AM
Feb-22-22 05:38AM
Jan-12-22 08:45AM
Jan-05-22 07:30AM
Dec-29-21 06:14AM
06:00AM
06:00AM
Dec-14-21 08:00AM
Dec-08-21 07:30AM
Nov-24-21 08:40AM
Nov-23-21 08:25AM
Nov-18-21 07:40AM
Nov-11-21 09:25AM
Nov-10-21 10:19AM
Nov-08-21 08:10AM
Nov-03-21 11:59AM
Oct-29-21 07:25AM
Sep-23-21 08:25AM
Sep-15-21 08:10AM
Sep-09-21 08:25AM
Aug-26-21 07:05AM
Aug-24-21 08:25AM
06:26AM
Aug-16-21 08:25AM
Aug-09-21 08:40AM
Aug-05-21 06:40AM
Jul-29-21 08:25AM
Jul-21-21 11:44AM
08:25AM
Jul-19-21 07:18AM
Jun-22-21 11:22AM
08:40AM
Jun-18-21 12:52PM
Jun-08-21 08:10AM
May-25-21 08:40AM
Apr-21-21 07:25AM
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.